The virus killer that takes on the nuclear threat of infection
“…I firmly believe that the Hemogenyx share price will follow our scientific and engineering and manufacturing promise…”
The founder of biopharmaceutical group Hemogenyx Pharmaceuticals compares the debilitating impact of viral infections to the destruction caused by nuclear weapons.
“A developed country can be brought to its knees by a bug that kills 0.1% of the population. It stops the economy and disrupts everything. It causes fear and people stop functioning.”
And with invasions and pandemics part of 21st century tragedies, Dr Vladislav Sandler isn’t exaggerating when he adds “Governments and very large institutions that are designed and created to take care of stability in a country must be interested in something that can prevent such a horrible event.”
He and his team are confident they’ve created ‘the something’ that can prevent an infection catastrophy. It’s the Chimeric Bait Receptor (CBR) platform technology which has achieved proof of concept. To put it simply, viruses are baited, entrapped and then extinguished.
Established in 2019 with a mission to tackle measles, the platform project was quickly amended to tackle the SARS-COV-2 virus. It worked on multiple variants of the Covid virus, and Sandler says the platform has demonstrated that it is a universal approach that can be used for “most known viruses.”
Sandler’s plan now is to try to partner with other companies or governments and push the platform into clinical trials particularly: “As we discovered recently it can be adapted for attracting and trapping malignant cells or cancer cells, and that opens a totally new area of application for CBR.”
Listen to Vlad tell Sarah Lowther about the very large patent application, why every year is a company making year, and the massive cost savings the custom-built laboratory will make for the company.
Read the company’s corporate presentation
Access SP Angel’s research note on #HEMO here
Follow the company on Twitter @HemogenyxPharma
The author was remunerated but does not hold shares in the company
